Scaleup programmes

Back to programmes

Programme

Alderley Park

Infrastructure

Impact for scaleups

205

Resident companies

Over 3,500

Employees

250

Members of Expert Mentor Network

2

Onsite venture funds

2.5X

Businesses likely to grow twice as fast as equivalent firms and raise 2.5 times more investment

Key sectors

Life Sciences & Biotech

Bruntwood SciTech’s Alderley Park provides over 1m sq ft of state-of-the-art office and lab space to businesses in the life sciences and tech sector as well as support for companies from start-up to scale up. There are now over 200 companies on site including national institutions such as Cancer Research UK and Medicines Discovery Catapult.

All companies on site have access to Alderley Park’s flexible infrastructure and scientific services, which allows them to expand as their business develops and grows. The Park is home to an extensive range of scientific services, including dedicated vivarium space and access to highly specialised suites including surgery, level 2 containment and bio-imaging. Coworking laboratories provide access to specialised equipment operated by an experienced laboratory management team on a pay-as-you-go basis.

Alderley Park is working with Medicines Discovery Catapult to build a Translational Research Facility in Infectious Disease which will build collaborations with scaling businesses and academics in infectious disease research. The new facility will provide critical infrastructure for future infection readiness, including a UK-leading category 3 biosafety (BSL3) facility to grow the capacity and capability of organisations working to validate diagnostics and treatments in infectious diseases.

The campus’ accelerator offers residents a 250+ expert mentor network, commercial workshops and bespoke one-to-one engagement and expertise for scaleup entrepreneurs and leaders. Workshops include a focus on the scaling challenges, leadership skills and development, access to finance and international markets. A peer to peer network is maintained through a weekly Directors’ call. Companies are helped to raise their profile through a new “customers and capabilities” web portal and workshops on comms strategies.

The Alderley Park Oncology Development Programme has made strong progress in its first year. Thirty-six applicants were selected to proceed to the Development Phase 1 of the initiative which aims to develop and nurture an entrepreneurial culture amongst cancer researchers and scaling businesses in the UK. The final six on the programme are set to innovate and disrupt oncology research and the objective that they will be ready to take on new funding or collaborators to present investable propositions ready to meet patients’ needs. Even before pitch day to pharma and VCs, companies have raised £16.2m.

                       

Alderley Park website